Nephrogenex Inc. (NRX) 13.35 $NRX
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 12:05PM CST
FATE: 5.03 (-0.62), SIBC: 20.72 (+5.36), FUR: 15.59 (-2.32), DRAM: 1.70 (-0.23), NRX: 13.35 (+8.70), MEIL: 1.36 (+0.35), MIG: 8.46 (+1.33), BCLI: 4.76 (+0.88), ABAC: 1.73 (-0.18), GBR: 1.51 (+0.23), NDRM: 14.04 (-4.10), RCMT: 7.00 (-1.55), AGRX: 6.14 (-0.56), REN: 1.32 (+0.28), KEG: 1.67 (-0.19), LIME: 2.93 (+0.52), CALA: 20.20 (+1.89), CJJD: 2.90 (-0.25), CBMG: 12.91 (+1.39), GNI: 13.90 (-1.90)
NephroGenex (NRX) Stock Skyrockets to One-Year High Today After Lead Drug Safety Announcement
at The Street - Wed Dec 31, 10:27AM CST
Shares of drug developer NephroGenex (NRX) exploded to a 52-week high Wednesday after the company announced it found its lead drug to be safe in a cardiac safety study.
NRX: 13.35 (+8.70)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 8:15AM CST
CYTK: 8.01 (+1.11), NEON: 3.38 (+0.30), ARWR: 7.38 (-0.19), NRX: 13.35 (+8.70), PEIX: 10.33 (-0.38), BCLI: 4.76 (+0.88), MIG: 8.46 (+1.33), NDRM: 14.04 (-4.10)
Daily Pharma Dose: New Research on Hospira, Aquinox, Sucampo, NephroGenex and OncoGenex
PR Newswire - Wed Dec 31, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Hospira (NYSE: HSP), Aquinox (NASDAQ: AQXP), Sucampo (NASDAQ: SCMP), NephroGenex (NASDAQ: NRX), and OncoGenex (NASDAQ: OGXI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AQXP: 7.50 (+0.25), OGXI: 2.29 (+0.06), NRX: 13.35 (+8.70), SCMP: 14.28 (+0.39), HSP: 61.25 (-1.31)
NephroGenex up big on Pyridorin safety study
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 7:52AM CST
NRX: 13.35 (+8.70)
NephroGenex Announces Positive Results for QT Study of Pyridorin
Business Wire - Tue Dec 30, 3:05PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the Company has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin. This study assesses a drug's risk of QT prolongation and its proarrhythmic potential, and is a standard component of all clinical development programs for new molecular entities.
NRX: 13.35 (+8.70)
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/6lddwg/acute_renal) has announced the addition of the "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Quark Pharmaceuticals, Inc. - FibroGen, Inc. - Novartis AG - Hadasit Medical Research Services & Development Ltd - NephroGenex, Inc. - Torrent Pharmaceuticals Limited - Digna Biotech, S.L. - Am-Pharma B.V. - AlloCure Inc. - Angion Biomedica Corp. - Thrasos, Inc. - Bolder Biotechnology, Inc. - Kringle Pharma, Inc. - Nephrx Corporation - STATegics, Inc. - ACROVIS biostructures GmbH - Nyken BV - AbbVie Inc. - Adrenomed AG For more information visit http://www.researchandmarkets.com/research/6l...cute_renal
NRX: 13.35 (+8.70), FGEN: 27.34 (+0.13), ABBV: 65.44 (-0.86), NVS: 92.66 (-0.55)
NephroGenex Announces Closing of $12 Million Term Loan Facility
Business Wire - Thu Nov 20, 3:05PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, announced today that it has closed on a $12 million term loan facility with East West Bank. Funds from the term loan will be utilized for working capital purposes, including the advancement of the Company's clinical development programs.
NRX: 13.35 (+8.70)
NephroGenex (NRX) CEO Pierre Legault on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 10:07AM CST
NRX: 13.35 (+8.70)
NephroGenex, Inc. Announces Presentation at the American Society of Nephrology's Kidney Week 2014
Business Wire - Thu Nov 13, 6:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, announced the presentation of the novel design of its Phase 3 Pyridorin PIONEER clinical program at the American Society of Nephrology (ASN) Kidney Week meeting held here November 11-16, 2014.
NRX: 13.35 (+8.70)
NephroGenex EPS of -$0.50
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:25PM CST
NRX: 13.35 (+8.70)
NephroGenex Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 12, 3:12PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the third quarter ended September 30, 2014.
NRX: 13.35 (+8.70)
NPS Pharma Appoints Pierre Legault to Board of Directors
Business Wire - Tue Nov 04, 3:30PM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced the appointment of Pierre Legault, MBA, CA, CPA to its board of directors. Mr. Legault is chief executive officer of NephroGenex, Inc. He previously served as CEO at Prosidion, Ltd. and has held senior positions at OSI Pharmaceuticals, Eckerd, Rite Aid Corporation, and Sanofi-Aventis.
NRX: 13.35 (+8.70), NPSP: 35.77 (+0.20)
NephroGenex Announces Date of Conference Call to Discuss Third Quarter 2014 Financial Results
Business Wire - Mon Nov 03, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report its third quarter 2014 financial results on Wednesday, November 12, 2014 after the U.S. financial markets close. The Company will host a conference call the following day, Thursday, November 13, 2014 at 8 a.m. Eastern, to review the third quarter 2014 financial results and provide an update on its PIONEER program for diabetic nephropathy and milestones for the remainder of 2014.
NRX: 13.35 (+8.70)
NephroGenex to Participate in Two Healthcare Conferences in November
Business Wire - Fri Oct 31, 7:00AM CDT
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer, Pierre Legault will present a corporate overview of the Company and meet with investors at the Bio-Europe(R) 2014 healthcare conference in Frankfurt, Germany.
NRX: 13.35 (+8.70)
NephroGenex Appoints Marco Taglietti, M.D. to Board of Directors
Business Wire - Wed Oct 01, 5:37AM CDT
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of Marco Taglietti, M.D., to its Board of Directors. Dr. Taglietti has more than 20 years of experience in senior leadership positions in pharmaceutical research and development, most recently at Forest Laboratories, Inc.
NRX: 13.35 (+8.70)
NephroGenex to Present at the 13th Annual Bio Investor Forum
Business Wire - Tue Sep 30, 7:01AM CDT
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Pierre Legault, Chief Executive Officer, will present a corporate overview of the Company and meet with investors at the 13th annual Bio Investor Forum at the Palace Hotel in San Francisco.
NRX: 13.35 (+8.70)
NephroGenex To Participate in Four Healthcare Conferences in September
Business Wire - Tue Sep 02, 7:01AM CDT
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer, Pierre Legault will present an overview of the Company and meet with investors at four healthcare conferences for institutional investors in September.
NRX: 13.35 (+8.70)
NephroGenex Reports Second Quarter 2014 Financial Results
Business Wire - Mon Aug 11, 3:30PM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the second quarter ended June 30, 2014.
NRX: 13.35 (+8.70)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 12:05PM CST
FATE: 5.03 (-0.62), SIBC: 20.72 (+5.36), FUR: 15.59 (-2.32), DRAM: 1.70 (-0.23), NRX: 13.35 (+8.70), MEIL: 1.36 (+0.35), MIG: 8.46 (+1.33), BCLI: 4.76 (+0.88), ABAC: 1.73 (-0.18), GBR: 1.51 (+0.23), NDRM: 14.04 (-4.10), RCMT: 7.00 (-1.55), AGRX: 6.14 (-0.56), REN: 1.32 (+0.28), KEG: 1.67 (-0.19), LIME: 2.93 (+0.52), CALA: 20.20 (+1.89), CJJD: 2.90 (-0.25), CBMG: 12.91 (+1.39), GNI: 13.90 (-1.90)
NephroGenex (NRX) Stock Skyrockets to One-Year High Today After Lead Drug Safety Announcement
at The Street - Wed Dec 31, 10:27AM CST
Shares of drug developer NephroGenex (NRX) exploded to a 52-week high Wednesday after the company announced it found its lead drug to be safe in a cardiac safety study.
NRX: 13.35 (+8.70)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 8:15AM CST
CYTK: 8.01 (+1.11), NEON: 3.38 (+0.30), ARWR: 7.38 (-0.19), NRX: 13.35 (+8.70), PEIX: 10.33 (-0.38), BCLI: 4.76 (+0.88), MIG: 8.46 (+1.33), NDRM: 14.04 (-4.10)
Daily Pharma Dose: New Research on Hospira, Aquinox, Sucampo, NephroGenex and OncoGenex
PR Newswire - Wed Dec 31, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Hospira (NYSE: HSP), Aquinox (NASDAQ: AQXP), Sucampo (NASDAQ: SCMP), NephroGenex (NASDAQ: NRX), and OncoGenex (NASDAQ: OGXI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AQXP: 7.50 (+0.25), OGXI: 2.29 (+0.06), NRX: 13.35 (+8.70), SCMP: 14.28 (+0.39), HSP: 61.25 (-1.31)
NephroGenex up big on Pyridorin safety study
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 7:52AM CST
NRX: 13.35 (+8.70)
NephroGenex Announces Positive Results for QT Study of Pyridorin
Business Wire - Tue Dec 30, 3:05PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the Company has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin. This study assesses a drug's risk of QT prolongation and its proarrhythmic potential, and is a standard component of all clinical development programs for new molecular entities.
NRX: 13.35 (+8.70)
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/6lddwg/acute_renal) has announced the addition of the "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Quark Pharmaceuticals, Inc. - FibroGen, Inc. - Novartis AG - Hadasit Medical Research Services & Development Ltd - NephroGenex, Inc. - Torrent Pharmaceuticals Limited - Digna Biotech, S.L. - Am-Pharma B.V. - AlloCure Inc. - Angion Biomedica Corp. - Thrasos, Inc. - Bolder Biotechnology, Inc. - Kringle Pharma, Inc. - Nephrx Corporation - STATegics, Inc. - ACROVIS biostructures GmbH - Nyken BV - AbbVie Inc. - Adrenomed AG For more information visit http://www.researchandmarkets.com/research/6l...cute_renal
NRX: 13.35 (+8.70), FGEN: 27.34 (+0.13), ABBV: 65.44 (-0.86), NVS: 92.66 (-0.55)
NephroGenex Announces Closing of $12 Million Term Loan Facility
Business Wire - Thu Nov 20, 3:05PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, announced today that it has closed on a $12 million term loan facility with East West Bank. Funds from the term loan will be utilized for working capital purposes, including the advancement of the Company's clinical development programs.
NRX: 13.35 (+8.70)
NephroGenex (NRX) CEO Pierre Legault on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 10:07AM CST
NRX: 13.35 (+8.70)
NephroGenex, Inc. Announces Presentation at the American Society of Nephrology's Kidney Week 2014
Business Wire - Thu Nov 13, 6:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, announced the presentation of the novel design of its Phase 3 Pyridorin PIONEER clinical program at the American Society of Nephrology (ASN) Kidney Week meeting held here November 11-16, 2014.
NRX: 13.35 (+8.70)
NephroGenex EPS of -$0.50
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:25PM CST
NRX: 13.35 (+8.70)
NephroGenex Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 12, 3:12PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the third quarter ended September 30, 2014.
NRX: 13.35 (+8.70)
NPS Pharma Appoints Pierre Legault to Board of Directors
Business Wire - Tue Nov 04, 3:30PM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced the appointment of Pierre Legault, MBA, CA, CPA to its board of directors. Mr. Legault is chief executive officer of NephroGenex, Inc. He previously served as CEO at Prosidion, Ltd. and has held senior positions at OSI Pharmaceuticals, Eckerd, Rite Aid Corporation, and Sanofi-Aventis.
NRX: 13.35 (+8.70), NPSP: 35.77 (+0.20)
NephroGenex Announces Date of Conference Call to Discuss Third Quarter 2014 Financial Results
Business Wire - Mon Nov 03, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report its third quarter 2014 financial results on Wednesday, November 12, 2014 after the U.S. financial markets close. The Company will host a conference call the following day, Thursday, November 13, 2014 at 8 a.m. Eastern, to review the third quarter 2014 financial results and provide an update on its PIONEER program for diabetic nephropathy and milestones for the remainder of 2014.
NRX: 13.35 (+8.70)
NephroGenex to Participate in Two Healthcare Conferences in November
Business Wire - Fri Oct 31, 7:00AM CDT
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer, Pierre Legault will present a corporate overview of the Company and meet with investors at the Bio-Europe(R) 2014 healthcare conference in Frankfurt, Germany.
NRX: 13.35 (+8.70)
NephroGenex Appoints Marco Taglietti, M.D. to Board of Directors
Business Wire - Wed Oct 01, 5:37AM CDT
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of Marco Taglietti, M.D., to its Board of Directors. Dr. Taglietti has more than 20 years of experience in senior leadership positions in pharmaceutical research and development, most recently at Forest Laboratories, Inc.
NRX: 13.35 (+8.70)
NephroGenex to Present at the 13th Annual Bio Investor Forum
Business Wire - Tue Sep 30, 7:01AM CDT
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Pierre Legault, Chief Executive Officer, will present a corporate overview of the Company and meet with investors at the 13th annual Bio Investor Forum at the Palace Hotel in San Francisco.
NRX: 13.35 (+8.70)
NephroGenex To Participate in Four Healthcare Conferences in September
Business Wire - Tue Sep 02, 7:01AM CDT
NephroGenex, Inc. (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer, Pierre Legault will present an overview of the Company and meet with investors at four healthcare conferences for institutional investors in September.
NRX: 13.35 (+8.70)
NephroGenex Reports Second Quarter 2014 Financial Results
Business Wire - Mon Aug 11, 3:30PM CDT
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the second quarter ended June 30, 2014.
NRX: 13.35 (+8.70)
